Figure 1From: Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II studyKaplan-Meier time to tumor progression (TTP) of patients treated with FOLFOX/Bevacizumab.Back to article page